GenMark Diagnostic

About:

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology.

Website: http://www.genmarkdx.com

Twitter/X: GenMarkDX

Top Investors: Biomedical Advanced Research and Development Authority (BARDA), GE Capital

Description:

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Total Funding Amount:

$110M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Carlsbad, California, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)genmarkdx.com

Founders:

Scott Mendel

Number of Employees:

501-1000

Last Funding Date:

2020-05-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai